In the wake of the U.S. Food and Drug Administration’s approval of Zepbound to treat moderate to severe obstructive sleep ...
Both of these GLP-1 drugs were originally designed for diabetes, but their benefits keep expanding — KSTP health expert Dr.
ResMed stock is down today, even though the maker of CPAPs and other respiratory treatment devices had Street-beating Q2 ...
LAKE CHARLES, La. (KPLC) - Nearly 40 million Americans struggle with sleep apnea, but a drug approved in December may help. The U.S. Food and Drug Administration calls Zepbound the first and only ...
KYW Radio Philadelphia on MSN2d
Medical Report: FDA approves weight loss drug to treat sleep apneaAs many as 17% of men and 34% of women in the United States suffer from sleep apnea, and the numbers are increasing. KYW ...
ResMed beat Wall Street estimates for second-quarter profit on Thursday, driven by strong demand for its devices used to manage sleep apnea, a common sleep disorder.
Eli Lilly investors and analysts said they want to hear details from the company on how exactly it plans to grow U.S. sales ...
Welcome to the Q2 fiscal-year 2025 ResMed earnings conference call. My name is Matt and I'll be your operator for today's call. (Operator Instructions) Please note that this conference call is being ...
Investor's Business Daily on MSN4d
ResMed Tumbles As Organic Sales Growth Steps Down. Will These 'Mega Trends' Save It?ResMed stock tumbled Friday after organic sales growth slowed somewhat in the second fiscal quarter. But one analyst was upbeat.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback